Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts

Metformin (MET) is a diabetes drug that activates AMP‐activated protein kinase (AMPK), and is suggested to have anticancer efficacy. Here, we investigated the role of AMPK signalling in prolactinoma (PRLoma), with particular respect to MET and bromocriptine (BC) as a PRLoma treatment. We analysed AM...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cell Mol Med
Main Authors: Gao, Jun, Liu, Yang, Han, Gaijing, Deng, Kan, Liu, Xiaohai, Bao, Xinjie, Feng, Ming, Yao, Yong, Lian, Wei, Xing, Bing, Lv, Xiang, Wang, Renzhi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6237574/
https://ncbi.nlm.nih.gov/pubmed/30334324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.13963
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados